Hepatoprotective properties of glycyrrhizic acid

The review is devoted to the problem of treatment of non-alcoholic fatty liver disease, which is the most common pathology of the hepato-biliary system worldwide and is characterized by an increasing frequency, including of more severe forms. A wide range of pathogenetic relationships of non-alcoholic fatty liver disease with diseases of other organ systems, primarily with diseases of the cardiovascular system, type 2 diabetes mellitus, chronic kidney disease and diseases of the biliary tract, is presented. The main mechanisms of comorbidity are insulin resistance, oxidative stress, inflammation, disorders of carbohydrate and fat metabolism. An approach to the therapy of this disease based on the concept of comorbidity has been substantiated. As a rational therapeutic choice, a molecule of glycyrrhizic acid is presented, which has pleiotropic effects, including anti-inflammatory, antioxidant, antifibrotic and immunomodulatory effects. The evidence base for glycyrrhizic acid is formed by a large array of clinical trials, including randomized placebo-controlled trials conducted both in Russia and abroad, in infectious and non-infectious liver diseases, including non-alcoholic fatty liver disease. Attention is focused on non-alcoholic fatty liver disease with intrahepatic cholestasis associated with a more severe course and high rates of disease progression. A theoretical justification for the use of a combination of glycyrrhizic acid and ursodeoxycholic acid in such patients is presented. The reason for this is the potential synergy of the two molecules, based on the induction of CYP3A4, and associated with the effect on inflammation, as a factor in the development of intrahepatic cholestasis and cholestasis itself.

1. Trifan А., Stanciu С., Jurcаu М., et al. Nonalcoholic steatohepatitis. A scientometric analysis of publications during 1980–2018. Medicine (Baltimore). 2019; 98 (50): e18221. doi: 10.1097/MD.0000000000018221.

2. Eslam M., Sanya A. J., George J. MAFLD: A ConsensusDriven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020;158(7):1999– 2014. DOI: 10.1053/j.gastro.2019.11.312.

3. Bang K.B., Cho Y. K. Comorbidities and Metabolic Derangement of NAFLD. Journal of Lifestyle Medicine. 2015; 5 (1): 7–13.

4. Käräjämäki A.J., Pätsi O.-P., Savolainen M., et al. NonAlcoholic Fatty Liver Disease as a Predictor of Atrial Fibrillation in Middle-Aged Population (OPERA Study). PLoS ONE. 2015; 10 (11): e0142937. doi:10.1371/journal.pone.0142937.

5. Fotbolcu H., Zorlu E. Nonalcoholic fatty liver disease as a multi-systemic disease. World J Gastroenterol. 2016; 22(16): 4079–4090.

6. Wu S., Wu F., Ding Y., et al. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: A systematic review and meta-analysis. Sci. Rep. 2016; 6: 33386. doi: 10.1038/srep33386.

7. Patil R., Sood G. K. Non-alcoholic fatty liver disease and cardiovascular risk. World J Gastrointest Pathophysiol. 2017; 8 (2): 51–58.

8. Hu K.C., Wang H. Y., Liu S. C., et al. Nonalcoholic fatty liver disease: Updates in noninvasive diagnosis and correlation with cardiovascular disease. World J Gastroenterol. 2014; 20 (24): 7718–7729.

9. Sinn D.H., Cho S. J., Gwak G. Y., et al. Nonalcoholic Fatty Liver Disease for Identification of Preclinical Carotid Atherosclerosis. Medicine. 2016; 95 (3): e2578. doi: 10.1097/MD.0000000000002578.

10. Bonci E., Chiesa C., Versacci P., et al. Association of Nonalcoholic Fatty Liver Disease with Subclinical Cardiovascular Changes: A Systematic Review and Meta-Analysis. BioMed Research International. 2015; 213737. Doi: 10.1155/2015/213737.

11. Mikolasevic I., Milic S., Turk Wensveen T., et al. Nonalcoholic fatty liver disease–A multisystem disease? World J Gastroenterol. 2016; 22(43): 9488–9505.

12. Yan L.H., Mu B., Guan Y., et al. Assessment of the relationship between non-alcoholic fatty liver disease and diabetic complications. J Diabetes Investig. 2016; 7 (6): 889–894.

13. Agafonova O. V., Gritsenko T. A., Bogdanova Yu.V., et al. Polyclinic therapy: Textbook. 2nd ed., Rev. and add. Moscow. GEOTAR-Media Publ., 2020. 840 P.

14. Colak Y., Bozbey G., Erim T., et al. Impaired Gallbladder Motility and Increased Gallbladder Wall Thickness in Patients with Nonalcoholic Fatty Liver Disease. J Neurogastroenterol Motil. 2016; 22 (3): 470–476.

15. Koller T., Kollerova J., Hlavaty T., et al. Cholelithiasis and markers of nonalcoholic fatty liver disease in patients with metabolic risk factors. Scand J Gastroenterol. 2012; 47(2): 197–203.

16. Xue J., Xin H., Ren N., et al. Nonalcoholic fatty liver disease increases the risk of gastroesophageal reflux disease: A systematic review and meta-analysis. Eur J Clin Invest. 2019; 49 (9): e13158. doi: 10.1111/eci.13158.

17. Wijarnpreecha K., Panjawatanan P., Thongprayoon C., et al. Association between gastroesophageal refl ux disease and nonalcoholic fatty liver disease: A meta-analysis. Saudi J Gastroenterol. 2017; 23(6): 311–317.

18. Fujiwara M., Eguchi Y., Fukumori N., et al. Th e Symptoms of Gastroesophageal Reflux Disease Correlate with High Body Mass Index, the Aspartate Aminotransferase/ Alanine Aminotransferase Ratio and Insulin Resistance in Japanese Patients with Non-alcoholic Fatty Liver Disease. InternMed. 2015; 54: 3099–3104.

19. Cheng D.D., He C., Ai H. H., et al. Th e Possible Role of Helicobacter pylori Infection in Non-alcoholic Fatty Liver Disease. Front. Microbiol. 2017; 8: 743. doi: 10.3389/fmicb.2017.00743.

20. Waluga M., Kukla M., Zorniak M., et al. From the stomach to other organs: Helicobacter pylori and the liver. World J Hepatol. 2015; 7(18): 2136–2146.

21. Che-yung Chao, Robert Battat, Alex Al Khoury, et al. Co-existence of non-alcoholic fatty liver disease and infl ammatory bowel disease: a review article. World J Gastroenterol. 2016; 22 (34): 7727–7734.

22. Nseir W., Artul S., Abu Rajab S., et al. Association between non-alcoholic fatty liver disease and hospitalized patients with community-acquired pneumonia. IMAJ. 2017; 19: 198.

23. Mantovani A., Lonardo A., Vinco G., et al. Association between non-alcoholic fatty liver disease and decreased lung function in adults: A systematic review and meta-analysis. Diabetes Metab. 2019; 45 (6): 536–544.

24. Li J.-Y., Cao H. Y., Liu P., et al. Glycyrrhizic Acid in the Treatment of Liver Diseases: Literature Review. BioMed Research International. 2014; Article ID872139. Doi: 10.1155/2014/872139.

25. Pastorino G., Cornara L., Soares S., et al. Liquorice (Glycyrrhizaglabra): A phytochemical and pharmacological review. Phytotherapy Research. 2018; 32: 2323–2339.

26. Selyutina O. Yu., Polyakov N. E. Glycyrrhizic acid as a multifunctional drug carrier – From physicochemical properties to biomedical applications: A modern insight on the ancient drug. International Journal of Pharmaceutics. 2019; 559: 271–279.

27. Moro T, Shimoyama Y, Kushida M, Hong YY, Nakao S, Higashiyama R, et al. Glycyrrhizin and its metabolite inhibit Smad3-mediated type I collagen gene transcription and suppress experimental murine liver fi brosis. Life Sci. 2008; 83(15–16): 531–9.

28. Murck H. Symptomatic Protective Action of Glycyrrhizin (Licorice) in COVID-19 Infection? Front. Immunol. 2020; 11:1239. doi: 10.3389/fimmu.2020.01239.

29. Luo P., Liu D., Li J. Pharmacological perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19. International Journal of Antimicrobial Agents. 2020. 105995. doi:10.1016/j.ijantimicag.2020.105995.

30. Bailly C., Vergoten G. Glycyrrhizin: An alternative drug for the treatment of COVID-19 infectionand the associated respiratory syndrome? Pharmacology & Th erapeutics. 2020. 107618. https://doi.org/10.1016/j.pharmthera.2020.107618.

31. Cai S, Bi Z, Bai Y et al. Glycyrrhizic Acid-Induced Differentiation Repressed Stemness in Hepatocellular Carcinoma by Targeting c-Jun N-Terminal Kinase 1. Front. Oncol. 2020; 9:1431. doi: 10.3389/fonc.2019.01431.

32. Shiota G., Harada K-I, Ishida M., et al. Inhibition of hepatocellular carcinoma by glycyr-rhizin in diethylnitrosamine-treated mice. Carcinogenesis. 1999; 20 (1): 59–63.

33. Khan R., Khan A. Q., Lateef A., et al. Glycyrrhizic Acid Suppresses the Development of Precancerous Lesions via Regulating the Hyperproliferation, Inflammation, Angiogenesis and Apoptosis in the Colon of Wistar Rats. PLoS One. 2013; 8(2): e56020. doi: 10.1371/journal.pone.0056020.

34. Ma D., Zhang J., Zhang Y., et al. Inhibition of myocardial hypertrophy by magnesium isoglycyrrhizinate through the TLR4/NF-κB signaling pathway in mice. IntImmunopharmacol. 2018; 55: 237–244.

35. Tang Q., Cao Y., Xiong W., et al. Glycyrrhizic acid exerts protective effects against hypoxia/reoxygenation-induced human coronary artery endothelial cell damage by regulating mitochondria. ExpTher Med. 2020; 20 (1): 335–342.

36. Cheng H.S., Magdelene J., Kong X. F., et al. Novel inhibitory effects of glycyrrhizic acid on the accumulation of advanced glycation end product and its receptor expression. Nat. Prod. Bioprospect. 2014. 4:325–333.

37. Hou S., Zheng F., Li Y., et al. Th e Protective Effect of Glycyrrhizic Acid on Renal Tubular Epithelial Cell Injury Induced by High Glucose. Int. J. Mol. Sci. 2014; 15: 15026–15043. doi: 10.3390/ijms150915026.

38. Fouladi S., Masjedi M., Hakemi M. G., et al. Th e review of in vitro and in vivo studies over the glycyrrhizic acid as natural remedy option for treatment of allergic asthma. Iran J Allergy Asthma Immunol. 2019; 18(1):1–11.

39. Huang Q.C., Wang M. J., Chen X. M., et al. Can active components of licorice, glycyrrhizin and glycyrrhetinic acid, lick rheumatoid arthritis? Oncotarget. 2015; 7 (2): 1193–1202.

40. Hung C.H., Kee K. M., Chen C. H., et al. A Randomized Controlled Trial of Glycyrrhizin Plus Tenofovir vs. Tenofovir in Chronic Hepatitis B with Severe Acute Exacerbation. Clinical and Translational Gastroenterology. 2017; 8, e104. doi:10.1038/ctg.2017.29.

41. van Rossum T. G.J., Vulto A.G, Hop W. C.J., et al. Glycyrrhizin-Induced Reduction of ALT in European Patients With Chronic Hepatitis C. The American Journal of Gastroenterology. 2001; 96 (8): 2432–2437.

42. van Rossum T. G.J., Vulto A.G, Hop W. C.J., et al. Intravenous Glycyrrhizin for the Treatment of Chronic Hepatitis C: A Double-Blinded, Randomised, PlaceboControlled Phase I/II Trial. Journal of Gastroenterology and Hepatology. 1999; 14: 1093–1099.

43. Orlent H., Hansen B. E., Willems M., et al. Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: A randomized phase II trial. Journal of Hepatology. 2006; 45: 539–546.

44. Manns M. P., Wedemeyer H., Singer A., et al. Glycyrrhizin in patients who failed previous interferon alpha-based therapies: biochemical and histological effects aft er 52 weeks. Journal of Viral Hepatitis. 2012; 19: 537–546.

45. Arase Y., Ikeda K., Murashima N., et al. Th e Long Term Efficacy of Glycyrrhizin in Chronic Hepatitis C Patients. Cancer. 1997; 79 (8): 1494–1500.

46. Ikeda K., Arase Y., Kobayashi M., et al. A Long-Term Glycyrrhizin Injection Therapy Reduces Hepatocellular Carcinogenesis Rate in Patients with Interferon-Resistant Active Chronic Hepatitis C: A Cohort Study of 1249 Patients. DigestiveDiseasesandSciences. 2006; 51 (3): 603–609.

47. Hansen B.E., Ikeda K., Veldt B. J., et al. Long-term follow-up of glycyrrhizin therapy in patients with chronic hepatitis C and non-response to interferon: Metaanalysis of individual patient data. Journal of Hepatology. 2003; 38(2): 143–144.

48. Hajiaghamohammadi A.A., Ziaee A., Samimi R. Th e Efficacy of Licorice Root Extract in Decreasing Transaminase Activities in Non-alcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial. Phytother. Res. 2012. doi: 10.1002/ptr.3728.

49. Chigurupati H., Auddy B., Biyani M., et a l. Hepatoprotective Effects of a Proprietary Glycyrrhizin Product during Alcohol Consumption: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study. Phytother Res. 2016; 30 (12):1943–1953.

50. Wei M., Liang-zhu Y., Li W., et al. Effects of Compound Glycyrrhizin on Liver Function in Patients with Alcoholic Liver Disease: a Meta-analysis. China Pharmacy. 2013; 24 (12). doi: 10.6039/j.issn.1001–0408.2013.12.22.

51. Ren C.A., Li Y. X., Cui J. Y., et al. Efficacy of glycyrrhizin combined with cyclosporine in the treatment of non-severe aplastic anemia. Chinese Medical Journal. 2013;126 (11): 2083–2086.

52. Yasui S., Fujiwara K., Tawada A., et al. Efficacy of Intravenous Glycyrrhizin in the Early Stage of Acute Onset Autoimmune Hepatitis. Dig Dis Sci. 2011; 56:3638– 3647.

53. Li L., Ma O., Li H. Effect of vitiligo treatment using compound glycyrrhizin combined with fractional carbon dioxide laser and topical triamcinolone acetonide on serum interleukin-17 and tissue growth factor-β levels. Journal of International Medical Research. 2019; 47 (11): 5623–5631.

54. Yu J.J., Zhang C. S., Coyle M. E., et al. Compound glycyrrhizin plus conventional therapy for psoriasis vulgaris: a systematic review and meta-analysis of randomized controlled trials. Curr Med Res Opin. 2017; 33 (2): 279–287.

55. Ipatova O. M. Phosphogliv: mechanism of action and clinical use. Monograph. Ed. Archakov A. I. Moscow. GU Research Institute of Biomedical Chemistry, Russian Academy of Medical Sciences Publ., 2005. 318 p.

56. Buyeverov A. O. Glycyrrhizinic acid: pathogenic treatment of chronic hepatitis c at specific groups of patients. Clinical perspectives of gastroenterology, hepatology. 2014; 4: 3–9.

57. Tsubota A., Kumada H., Arase Y., et al. Combined ursodeoxycholic acid and glycyrrhizin therapy for chronic hepatitis C virus infection: a randomized controlled trial in 170 patients. Eur J Gastroenterol Hepatol. 1999; 11(10): 1077–1083.

58. Vyuchnova E. S., Maev I. V., Babina S. M. Th e eff ectiveness of essential phospholipids in the treatment of patients with non-alcoholic steatohepatitis. Clinical perspectives of gastroenterology, hepatology. 2010; 3: 3–11.

59. Ivashkin V. T., Bakulin I. G., Bogomolov P. O., et al. Efficacy and safety of glycyrrhizic acid combined to essential phospholipids (Phosphogliv) at non-alcoholic fatty liver disease: results of multicenter double blind randomized placebo-controlled post-registration clinical study (IV phase) «Gepard» (PHG-M2/P02– 12). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(2):34–43. (In Russ.) https://doi.org/10.22416/1382–4376–2017–27–2–34–43

60. Mekhtiev S. N. Prospects for the complex therapy of patients with alcoholic liver disease with severe stages of fibrosis. EF. Gastroenterology. 2011; 2: 15–22.

61. Nikitin I. G., Baikova I. E., Volynkina V. M. et al. Experience of using glycyrrhizic acid in the treatment of patients with alcoholic liver disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2009;(1):53–58. (In Russ.)

62. Bakulin I. G., Bokhan N. A., Bogomolov P. O., et al. Efficacy and safety of glycyrrhizic acid and essential phospholipids (Phosphogliv) combination for alcoholic liver disease: results of the double-blind randomized placebo-controlled multicenter post-registration (phase IV) clinical trial «Jaguar» (PHG-M2/P03–12). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(3):57–68. (In Russ.) doi: 10.22416/1382–4376–2017–27–3–57–68

63. Novikova T. I., Novikov V. S. Experience of using the drug «Phosphogliv» in the treatment of liver damage against the background of chemotherapy of the lungs. Tuberculosis and lung diseases. IX Congress of phthisiatricians of Russia: conference proceedings. 2011. No. 5, 76 P.

64. Shipovskaya A.A., Dudanova O. P. Intrahepatic cholestasis in nonalcoholic fatty liver disease. TerArkh. 2018;90(2):69–74.

65. Chen J., Zhao K. N., Chen C. Th e role of CYP3A4 in the biotransformation of bile acids and therapeutic implication for cholestasis. Ann Transl Med. 2014; 2(1): 7. doi: 10.3978/j.issn.2305–5839.2013.03.02.

66. Woolsey S.J., Mansell S. E., Kim R. B., et al. CYP3A Activity and Expression in Nonalcoholic Fatty Liver Disease. Drug MetabDispos. 2015; 43:1484–1490.

67. Wu S.Y., Cui S. C., Wang L., et al. 18β-Glycyrrhetinic acid protects against alpha-naphthylisothiocyanate-induced cholestasis through activation of the Sirt1/FXR signaling pathway. ActaPharmacol Sin. 2018; 39(12): 1865–1873.

68. Yan T., Wang H., Cao L., et al. Glycyrrhizin alleviates nonalcoholic steatohepatitis via modulating bile acids and meta-inflammation. Drug MetabDispos. 2018; 46(9): 1310–1319. doi: 10.1124/dmd.118.082008.

69. Tu J., He Y., Chen Y., et al. Effect of glycyrrhizin on the activity of CYP3A enzyme in humans. Eur J ClinPharmacol. 2010; 66: 805–810.